Hemispherx’s Ampligen Poised To Become First Approval For Chronic Fatigue Syndrome
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA staff scheduling changes are behind a 1-2 week delay of action on May 25 user fee goal.
You may also be interested in...
Chronic Fatigue Drug Moving Slowly: Hemispherx's Ampligen Gets "Complete Response"
FDA wants more of everything, from clinical trials to resolution of manufacturing issues.
Chronic Fatigue Drug Moving Slowly: Hemispherx's Ampligen Gets "Complete Response"
FDA wants more of everything, from clinical trials to resolution of manufacturing issues.
Chronic Fatigue Drug Moving Slowly: Ampligen Gets "Complete Response"
FDA's "complete response" letter for Hemispherx Biopharma's Ampligen cites the full gamut of problems that could have come up for the NDA